NFKB1 and mantle cell lymphoma: Using ten MCL cell lines, (four sensitive and six resistant to ibrutinib), they found that sensitive cell lines display chronic activation of BCR signaling, whereas resistant lines were dependent on the MAP3K14-NF-κB pathway leading to NF-κB activation [37].